1. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Issue 12 (December 2022) Authors: Soileau, Michael J; Aldred, Jason; Budur, Kumar; Fisseha, Nahome; Fung, Victor SC; Jeong, Anna; Kimber, Thomas E; Klos, Kevin; Litvan, Irene; O'Neill, Daniel; Robieson, Weining Z; Spindler, Meredith A; Standaert, David G; Talapala, Saritha; Vaou, Eleni Okeanis; Zheng, Hui; Facheris, Maurizio F; H... Journal: Lancet neurology Issue: Volume 21:Issue 12(2022) Page Start: 1099 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗